A sustainable antimicrobial business
NexaBiome Life Sciences is developing products that can have a profound impact on human health but which also overcome the commercial challenges that often prevent antimicrobial companies growing sustainable platforms.

The average cost of developing a new antimicrobial.
Average annual sales of a new antimicrobial, as stewardship measures restrict use to help slow resistance.
The share of pharmaceutical venture capital invested in antibacterials.
Source: Gargate, N., Laws, M. & Rahman, K.M. Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria. npj Antimicrobials and Resistance 3, 50 (2025). https://doi.org/10.1038/s44259-025-00123-1
A path to sustainable products
At NexaBiome Life Sciences we know that when developing new antimicrobials, the technical challenge is only half the battle. That's why we have developed a robust development and clinical programme that not only addresses the question of "Will it work?" but also "Can we build a sustainable business?".
We are preparing to take our first product, a room-temperature-stable wound dressing for diabetic foot infections, through clinical development. We are working with the UK National Health Service to design a clinical trial that will efficiently prove the value in the product, and with the UK Medicines and Healthcare products Regulatory Agency to ensure the product is sustainable and commercially viable.
Our sustainable development and commercial viability relies on three key aspects:
Targeting an urgent unmet need.
Developing products in a way that gets to market faster and for less money.
Developing products that address bacterial resistance and enable a viable, sustainable business model.
Antimicrobial stewardship and subscription models
Antimicrobial stewardship refers to the responsible use of antimicrobials, with the goal of delaying the development of resistance. In practice, this often means limiting the use of the most effective antimicrobials. This leads to a paradoxical situation where the latest therapies are only used as treatments of last resort, when other established therapies have failed.
This is a serious problem for new antibiotics, which cost over a billion dollars to develop but which are not widely used, particularly in the relatively short window where patent protection exists and the majority of profits would typically be made.
Many countries are now addressing this problem by developing subscription models, where companies can receive payment to make an antimicrobial available, whether it is used or not, but these do not (yet) cover the cost of development, are still being developed and each has different acceptance criteria.
Ideally, for a new antimicrobial to succeed and be sustainable, it should have a route to commercial viability that does not rely on subscription models.

Advancing into clinical development
The biological and evolving nature of phages allows us to update the product in response to development of resistance (if it occurs), without performing additional clinical trials. This addresses a key challenge associated with antimicrobial stewardship and supports a traditional business plan that does not rely on subscription models. The use of phages in our DFI wound dressing also derisks many of the steps in the development process, such as manufacture and toxicology. The various compassionate use trials conducted with phages and DFIs, which demonstrate efficacy in the most severe cases, also give a strong indication that the product will work in patients.
Together, these factors support the commercial potential of our lead product. Beyond representing a viable stand-alone opportunity, its development also validates our patented stabilisation platform and demonstrates our ability to rapidly develop new products and deliver them to patients.
We are currently raising capital to advance our product into clinical development. To discuss the investment opportunity and our wider platform, please contact us.
Independent health economic analysis
Healthcare Improvement Scotland conducted an independent analysis on the value bacteriophage therapies could bring to patients. This analysis looked exclusively at costs saved by preventing amputation, not other associated health costs, and it only considered patients who had run out of options, apart from amputation.
Its report found that phage treatment not only improved patient outcomes, it also nearly halved the average cost of treatment per patient, due to the prevention of limb amputations. This ability to both improve patient outcomes and save money is known as a dominant intervention.
Even with the restricted analysis, it was estimated that phage therapy plus standard of care has an approximate 85% probability of being cost effective, using a willingness-to-pay threshold of £20,000 per quality-adjusted life year (QALY). This equates to a willingness to pay of around £50,000 per course.

Average total cost per patient
-
Standard of care £10,759
-
Phage therapy plus standard of care £5,750
Quality-adjusted life years
-
Standard of care 0.462
-
Phage therapy plus standard of care 0.726
Source: Scottish Health Technologies Group, Healthcare Improvement Scotland. Bacteriophage therapy for patients with difficult to treat bacterial infections. https://shtg.scot/our-advice/bacteriophage-therapy-for-patients-with-difficult-to-treat-bacterial-infections/
Explore the investment opportunity
Talk to the team about our technology, development strategy and path towards commercialisation.